BAUSCH & LOMB PUREVISION (BALAFILCON A) VISIBILITY TINTED CONTACT LENSES-THERAPEUTIC USE

Lenses, Soft Contact, Extended Wear

FDA Premarket Approval P980006 S007

This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.

Pre-market Approval Supplement Details

Approval for adding a therapeutic indication for the purevision contact lens. The device, as modified, will be marketed under the trade name bausch & lomb purevision (balafilcon a) visibility tinted contact lens for therapeutic use and is indicated for therapeutic use as a bandage contact lens for corneal protection and corneal pain relief during treatment of ocular pathologies as well as post-surgical conditions. Applications of the purevision contact lens include but are not limited to conditions such as the following: 1) for corneal protection in conditions such as entropion, trichiasis, tarsal scars, recurrent corneal erosion and post surgical ptosis for corneal protection; 2) for corneal pain relief in conditions such as bullous keratopathy, epithelial erosion and abrasion, filamentary keratitis, post-keratoplasty; 3) for use as a bandage during the healing process of conditions such as chronic epithelial defects, corneal ulcer, neurotrophic keratitis, neuroparalytic keratitis, chemical burns, and post surgical epithelial defects; and 4) for post surgical conditions that include bandage use such as lasik, prk, pk, ptk, lamellar grafts, corneal flaps, and additional corneal surgical conditions. Pure vision contact lenses for therapeutic use can also provide correction during healing if required.

DeviceBAUSCH & LOMB PUREVISION (BALAFILCON A) VISIBILITY TINTED CONTACT LENSES-THERAPEUTIC USE
Classification NameLenses, Soft Contact, Extended Wear
Generic NameLenses, Soft Contact, Extended Wear
ApplicantBausch & Lomb, Inc.
Date Received2005-03-03
Decision Date2005-05-27
PMAP980006
SupplementS007
Product CodeLPM
Advisory CommitteeOphthalmic
Supplement TypeNormal 180 Day Track
Supplement ReasonLabeling Change - Indications/instructions/shelf Life/tradename
Expedited ReviewNo
Combination Product No
Applicant Address Bausch & Lomb, Inc. 1400 North Goodman St. rochester, NY 14609-3547

Supplemental Filings

Supplement NumberDateSupplement Type
P980006Original Filing
S035 2022-08-12 30-day Notice
S034 2022-02-22 30-day Notice
S033 2021-12-15 30-day Notice
S032 2021-06-03 Real-time Process
S031
S030 2020-09-02 30-day Notice
S029 2019-07-15 Real-time Process
S028
S027 2018-03-12 30-day Notice
S026 2017-12-26 30-day Notice
S025 2015-11-20 30-day Notice
S024 2015-02-20 30-day Notice
S023 2014-09-15 30-day Notice
S022 2014-04-14 Normal 180 Day Track No User Fee
S021 2013-06-24 30-day Notice
S020 2011-06-08 30-day Notice
S019 2011-05-19 30-day Notice
S018 2010-12-03 Normal 180 Day Track No User Fee
S017 2010-12-01 30-day Notice
S016 2010-12-01 30-day Notice
S015 2010-07-22 Normal 180 Day Track
S014 2008-11-12 Real-time Process
S013 2008-09-24 Real-time Process
S012 2008-04-02 Real-time Process
S011 2007-08-20 30-day Notice
S010 2006-08-24 30-day Notice
S009
S008 2005-04-25 Real-time Process
S007 2005-03-03 Normal 180 Day Track
S006 2005-02-03 Real-time Process
S005 2004-01-06 Normal 180 Day Track No User Fee
S004 2001-05-30 Panel Track
S003 2001-01-09 Normal 180 Day Track
S002 1999-09-01 Normal 180 Day Track
S001 1999-06-29 Normal 180 Day Track

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.